AuBEX Corp

AuBEX Corp maintains a strong liquidity position, with cash and equivalents amounting to ¥2.85 billion, representing 28.96% of total assets. The company's liquidity FPT (free cash flow to total liabilities) is 1.98, indicating a robust ability to meet short-term obligations. The current ratio of 4.02 further supports this, showing that current assets significantly exceed current liabilities. Profitability metrics show that AuBEX Corp's return on equity (ROE) is 8.65%, and return on assets (ROA) is 5.89%. These figures are in line with the industry's preferred metrics, which emphasize asset efficiency and equity returns. The company's operating margin is 13.91%, and net profit margin is 9.61%, both of which are strong indicators of operational efficiency and cost control. The company's revenue is distributed across two primary segments: Techno Products and Medical Products. The Techno Products segment focuses on pen tips for stationery and cosmetics, while the Medical Products segment includes pressurized pharmaceutical syringes and angiographic guidewires. There is no disclosed geographic concentration, but the company's operations are primarily based in Japan. Looking ahead, AuBEX Corp is projected to maintain a stable growth trajectory. The current fiscal year (FY) outlook indicates a revenue growth of 0.00%, with the next FY expected to show a similar trend. This suggests a conservative approach to growth, likely influenced by market conditions and operational capacity. Risk factors for AuBEX Corp are currently assessed as low, with no immediate filing-based liquidity or dilution flags detected. The company's debt-to-equity ratio is 0.22, indicating a conservative capital structure with limited leverage. The risk assessment also notes a low dilution potential, supported by the absence of recent equity issuance or shelf registration activity. Recent events and filings for AuBEX Corp have not indicated any significant changes in the company's operations or financial strategy. The latest actual EPS is 209.05 JPY, and the actual revenue is ¥6.04 billion, aligning with the company's reported financial performance. No major regulatory or operational disruptions have been reported in the latest filings.